Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 217 от 240

Активно (без набиране)

Mepolizumab and Physical Activity in Severe Asthma

Asthma Asthma; Eosinophilic

Severe asthma is a debilitating condition associated with frequent symptoms, life-threatening exacerbations and corticosteroid side-effects. Exercise limitation due to exercise-induced bronchoconstriction, dynamic lung hyperinflation and comorbidity may be a strong determinant of the disease burden. Mepolizumab is a monoclonal anti-interleukin-5 (IL-5) antibody that reduces the rate of severe exacerbations, asthma symptoms and oral glucocorticoid requirement, and improves quality of life and work productivity in severe eosinophilic asthma. However, its impact on physical activity and exercise tolerance is unknown. We hypothesize that a 6-month treatment with mepolizumab is associated with an improvement in daily life physical activity and exercise tolerance in relation with enhanced ventilatory mechanics.

Начало: 02.02.2023 Край: 02.08.2026 Възраст: 18–75 г.

France University Hospital, Lille NCT05404763

Активно (без набиране)

Assessment of Biomarkers in Children to Help Parents Quit Tobacco

Tobacco Dependence

This randomized controlled trial will test whether adding biomarker measurement and informed outreach for tobacco smoke exposure as part of routine practice increases identification and improves treatment, effectiveness, and sustainability of a parental tobacco control intervention that will be integrated into pediatric practice.

Начало: 20.01.2023 Край: 01.06.2026 Възраст: от 18 г.

United States Massachusetts General Hospital NCT04832659

Активно (без набиране)

Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients

Lung Cancer, Nonsmall Cell

The purpose of this study is to examine the association between ctDNA/immune biomarkers and disease progression in patients who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of immune checkpoint inhibitor monotherapy or immune checkpoint inhibitor combination chemotherapy for mNSCLC.

Начало: 17.01.2023 Край: 01.09.2035 Възраст: от 18 г.

United States Wake Forest University Health Sciences NCT05415358

Активно (без набиране)

A Naturalistic Trial of the Norwegian Sickness Absence Clinic. The NSAC Efficacy Study

Musculoskeletal Disorder Anxiety Disorders Depression Fatigue +7

The Norwegian Sickness Absence Clinic (NSAC) is a publicly funded specialist outpatient health service, which is uniquely available for the work force. The overall aim of the NSAC is prevention of sickness absence, promote return to work (RTW) among those on sickness absence and prevent long term disability benefit dependency. In addition to being a health service, the NSAC has a focus on work and functional recovery, including also non-health related factors. Patients can be referred by general practitioners for mental health problems and musculoskeletal problems. The NSAC has a lower threshold for severity than specialist health services generally, and in particular for mental health problems. The efficacy of this service is unknown. The NSAC Efficacy Study is a randomized controlled multicentre trial which aims to assess the effect of the NSAC service. "Helse i Arbeid" is the Norwegian name for NSAC, and the Norwegian abbreviation is "HiA". The Norwegian study name is HIANOR. The NSAC Efficacy Study involves five different NSACs across northern Norway, and will recruit 2500 patients, randomized to in equal proportions to three treatment arms: 1. NSAC - rapid: treatment at the NSAC at- or within 4 weeks 2. NSAC - ordinary: treatment at the NSAC after 10-14 weeks 3. NSAC - active control: monodisciplinary examination at the NSAC close to diagnosis-specific deadline for examination as suggested by guidelines (8-26 weeks, the majority at the end of this interval) The overall aim is to assess the effect of the NSAC service, with the hypothesis that the NSAC service is superior to what resembles treatment as usual (TAU) for outcomes such as return to work or improved health (waiting list control). Many of the diagnoses or problems for which patients are referred to the NSACs naturally improve regardless of health interventions, and - as of date - no research has been conducted to assess the efficacy of the service.

Начало: 16.01.2023 Край: 01.10.2034 Възраст: от 18 г.

Norway Nordlandssykehuset HF NCT05310695

Активно (без набиране) Фаза 2

Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

Erythroplakia Oral Leukoplakia

This phase IIb trial tests whether metformin works in preventing oral cancer in patients with oral leukoplakia (white patches) or erythroplakia (red patches). Metformin is in a class of drugs called biguanides. Metformin helps to control the amount of glucose (sugar) in the blood. It decreases the amount of glucose patients absorb from food and the amount of glucose made by the liver. Metformin also increases the body's response to insulin, a natural substance that controls the amount of glucose in the blood. This trial may help researchers determine if metformin can stop changes in the mouth that are related to pre-cancer growths in the mouth.

Начало: 12.01.2023 Край: 01.12.2026 Възраст: от 21 г.

Canada, United States University of Arizona NCT05237960

Активно (без набиране)

Melatonin and Sleep Spindles in Autism

Autism Spectrum Disorder

Sleep disturbances and sensory sensitivities are common disabling features of autism, but their underlying causes are not clear. We hypothesize that both of these difficulties reflect disrupted communication between a deep brain structure, the thalamus, and the brain's outer layer, the cortex. This communication is mediated by the thalamic reticular nucleus (TRN). Due to its small size and location deep in the brain, we cannot assess TRN function without invasive techniques. Fortunately, sleep spindles, a specific brain rhythm provide a noninvasive read-out of TRN function. In Aim 1 we will examine whether reduced sleep spindles are related to worse sleep quality, impaired selective attention during wake, and sensory sensitivities in children with autism. In Aim 2, we will determine whether melatonin, which is commonly used to improve sleep, also increases sleep spindles in autism. If successful, this study will introduce TRN as a target for treatment of sleep disruption and guide larger home-based sleep studies.

Начало: 11.01.2023 Край: 01.01.2027 Възраст: 12–18 г.

United States Massachusetts General Hospital NCT05716906

Активно (без набиране) Фаза 2

NP137 Clinical and Biological Activities Assessment in Patients With Advanced/Metastatic Solid Tumors Treated by Standard Anti PD-1/PD-L1 Immunotherapies

Advanced Solid Tumors Metastatic Solid Tumors

This study is a multicenter, open-label, proof-of-concept study aiming to assess the clinical and biological impact of NP137 when added to standard PD-1/PD-L1 blockade therapy in 3 independent cohorts of advanced or metastatic solid tumors with various sensitivity to anti-PD-1/PD-L1: * Cohort 1 \[Stable Disease\]: Patients with a radiological documentation of SD according to RECIST V1.1 criteria following at least 12 weeks under standard anti PD-1/PD-L1 therapy. Note: This treatment arm closed on 27/09/2024 due to non-feasibility. * Cohort 2 \[primary refractory\]: Patients with documented radiological PD or short-term SD (\< 6months) according to RECIST V1.1 but with clinical benefit under PD-1/PD-L1 standard therapy. * Cohort 3 \[secondary refractory\]: Patients with documented radiological PD following an initial Objective Response or long-term SD (i.e. ≥6 months) according to RECIST V1.1, with clinical benefit under standard PD-1/PD-L1.

Начало: 06.01.2023 Край: 01.01.2027 Възраст: от 18 г.

France Centre Leon Berard NCT05605496

Активно (без набиране)

Use of Transcranial Photobiomodulation to Improve Cognition and Self-Reported Outcomes in Survivors of Childhood Cancer

ALL Hodgkin Lymphoma Cancer Survivorship

Survivors of childhood cancer are at greater risk for long-term cognitive impairments that include attention, executive function, intelligence, memory, and processing speed. The participants are a survivor of acute lymphoblastic leukemia (ALL) or Hodgkin's lymphoma (HL). Because of your treatment the participant may have developed trouble with thinking and learning. Primary Objective To evaluate the feasibility of using home-based tPBM paired with remote cognitive training to improve cognitive performance in survivors of ALL and HL. Secondary Objectives To estimate the potential efficacy of alpha and gamma frequency tPBM on cognitive performance in survivors of ALL and HL. Exploratory Objectives To estimate the effects of home-based tPBM paired with remote cognitive training on patient reported symptoms of executive dysfunction, sleep, depression, anxiety, fatigue, and pain in survivors of ALL and HL.

Начало: 05.01.2023 Край: 01.08.2026 Възраст: от 18 г.

United States St. Jude Children's Research Hospital NCT05550948

Активно (без набиране)

Safety and Efficacy of Distal Radial Access (SAFE-BOX)

Safety Efficacy

A Prospective Registry to assess the Safety and Efficacy of Distal Radial Approach

Начало: 05.01.2023 Край: 31.12.2026 Възраст: от 20 г.

South Korea Yonsei University NCT05776550

Активно (без набиране) Фаза 1/2

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG

Brain Tumor

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric patients

Начало: 04.01.2023 Край: 01.10.2026 Възраст: 5–18 г.

Canada InSightec NCT05615623

Активно (без набиране) Фаза 1/2

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)

Brain Tumor

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric patients

Начало: 04.01.2023 Край: 01.10.2026 Възраст: 5–21 г.

United States InSightec NCT05630209

Активно (без набиране) Фаза 1

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Cutaneous Melanoma Non-small Cell Lung Cancer Colorectal Neoplasms Pancreatic Neoplasms +1

This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. This study will have 3 parts. Parts A and B of the study will find out how much PF-08046049/SGN-BB228 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046049/SGN-BB228 is safe and if it works to treat solid tumor cancers.

Начало: 03.01.2023 Край: 06.06.2026 Възраст: от 18 г.

Canada, France, Germany +3 Seagen, a wholly owned subsidiary of Pfizer NCT05571839

Активно (без набиране) Фаза 3

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

NSCLC

This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).

Начало: 29.12.2022 Край: 01.11.2027 Възраст: 18–130 г.

Austria, Brazil, Bulgaria +20 AstraZeneca NCT05687266

Активно (без набиране)

Study Comparing Arthrodesis Technique of Thoracic and/or Lumbar Spine by Posterior Approach Performed by Robot-assisted Surgery (Robot Mazor X Stealth ™) Versus Conventional Surgery

Osteosynthesis Mazor Robot Spinal Surgery Arthrosis; Spine

Osteosynthesis by pedicle screwing is the reference technique since the 1980s, due to the quality of the mechanical grip of the screw in the pedicle, despite difficulties of placing the implant in this narrow tunnel. This precision was improved by fluoroscopy, then by navigation, which made it possible to reduce the extra-pedicular placement of the screws and consequently the complications. Since the 2000s, robotic has been developed in all areas, including medicine and surgery, (Da Vinci robot in urology) and several robots are currently marketed for spinal surgery, Medtronic's Mazor X Stealth ™ robot being the most successful. The aim of this study is to evaluate on a prospective randomized comparative study the quality of the placement of the screws as well as the occurrence of complications, the clinical results and the medico-economic interest that robotic surgery can bring.

Начало: 26.12.2022 Край: 01.01.2028 Възраст: от 18 г.

France Elsan NCT05553028

Активно (без набиране)

An Evaluation of Concordance of Smartwatch ECG and One Clinical ECG and Comparison of The Two ECGS in Terms of Predictive Risks

Childhood Cancer Cardiomyopathy, Primary

The participant is being asked to take part in this trial, because the participant is a survivor of childhood cancer. Primary Objective To evaluate remote cardiomyopathy prediction via smartwatch and one clinical ECG and assess the concordance of the two ECGs in terms of predicted risk. Secondary Objective To build a novel predictive model solely on smartwatch ECG to predict risk for cardiomyopathy.

Начало: 13.12.2022 Край: 01.06.2027 Възраст: от 22 г.

United States St. Jude Children's Research Hospital NCT05617391

Активно (без набиране) Фаза 2

UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly

Glioblastoma Multiforme, Adult Glioblastoma, IDH-mutant

The usual standard of care for patients over 65 diagnosed with glioblastoma ("GBM") or Grade 4 astrocytoma, IDH-mutant is a 3-week course of radiotherapy, with concurrent and adjuvant temozolomide (TMZ). This radiation dose and length of treatment are less than what would be given for younger patients, primarily due to unclear survival benefits from randomized trials. However, survival remains dismal, and may be partially due to the reduced radiation dose. Recent studies investigating this have found that increased radiation dose (to the equivalent of what is normally given over 6 weeks in younger patients) over 3 weeks is well-tolerated and has improved survival rates. Additionally, with the advent of novel technology such as the MR-Linac, adaptive radiotherapy with this regimen using reduced radiation margins is possible. Use of the MR-Linac allows for daily MRI scans to be done prior to treatment, so plans can be adapted to tumour dynamics and anatomical deformations. In this trial, we will examine the outcomes of increased radiation dose, combined with reduced-margin adaptive radiotherapy in this patient population.

Начало: 13.12.2022 Край: 31.12.2028 Възраст: от 65 г.

Canada Sunnybrook Health Sciences Centre NCT05565521

Активно (без набиране) Фаза 1

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)

Diabetic Macular Edema

This study will assess the safety and tolerability of RO7497372 in participants with DME. The study consists of 2 parts. Part 1 will test multiple-ascending doses of RO7497372 after unilateral intravitreal (IVT) administration in participants with DME. The main purpose of Part 1 is to provide data for RO7497372 safety and tolerability, as well as to characterize the ocular and systemic pharmacokinetics (PK), systemic anti-drug antibodies (ADA), and duration of target engagement, i.e., the pharmacodynamics (PD) in aqueous humor (AH) and blood. Part 2 will evaluate the safety, tolerability, PK, and PD of two dose strengths of RO7497372 (low dose and high dose), identified as safe and tolerated in Part 1.

Начало: 08.12.2022 Край: 12.01.2027 Възраст: от 18 г.

Puerto Rico, United States Genentech, Inc. NCT06847854

Активно (без набиране) Фаза 2

Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

Resectable Sarcoma

Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to assess the antitumor activity of retifanlimab (INCMGA00012) in association with neoadjuvant chemotherapy

Начало: 07.12.2022 Край: 01.04.2028 Възраст: от 18 г.

France Institut Bergonié NCT04968106

Активно (без набиране)

Motivational Interviewing to Address Suicidal Ideation for Veterans at High Risk for Suicide

Suicide, Attempted Suicidal Ideation

The purpose of this project is to conduct a randomized control trial with 470 Veterans to examine the impact of a revised version of Motivational Interviewing to Address Suicidal Ideation (MI-SI-R) on risk for suicide attempts and suicidal ideation when compared to high quality usual care.

Начало: 30.11.2022 Край: 29.06.2027 Възраст: от 18 г.

United States VA Office of Research and Development NCT05256940

Активно (без набиране) Фаза 3

Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

The purpose of this study is to evaluate the safety and efficacy of ALXN1720 for the treatment of generalized MG (gMG) in adults with autoantibodies against acetylcholine receptor (AChR).

Начало: 21.11.2022 Край: 31.08.2027 Възраст: от 18 г.

Argentina, Austria, Brazil +19 Alexion Pharmaceuticals, Inc. NCT05556096

1 … 215 216 217 218 219 … 240